HCW Biologics (HCWB) Share-based Compensation (2020 - 2025)
HCW Biologics' (HCWB) quarterly Share-based Compensation came in at $9182.0 in Q4 2025, down 96.86% YoY from $292071.0 in Q4 2024, and down 95.53% on a QoQ basis from $205492.0 in Q3 2025.
HCW Biologics (HCWB) Share-based Compensation (2020 - 2025) Analysis & Trends
HCW Biologics (HCWB) has 6 years of Share-based Compensation data on file, last reported at $9182.0 in Q4 2025.
- Quarterly Share-based Compensation fell 96.86% year-over-year to $9182.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $768623.0 (down 23.82% YoY) and the FY2025 annual result came in at $768623.0, down 23.82% from the prior year.
- Share-based Compensation fell to $9182.0 in Q4 2025, from $205492.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $349097.0 in Q4 2021 to a low of $1660.0 in Q3 2021.
- A 5-year average of $236240.6 and a median of $260810.0 in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 18112.05% — and 2025, when it sank 96.86%.
- Tracing HCWB's Share-based Compensation over 5 years: stood at $349097.0 in 2021, then dropped by 18.02% to $286188.0 in 2022, then slipped by 8.71% to $261272.0 in 2023, then gained by 11.79% to $292071.0 in 2024, then slumped by 96.86% to $9182.0 in 2025.
- The last three Share-based Compensation figures came in at $9182.0 (Q4 2025), $205492.0 (Q3 2025), and $278307.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | HCW Biologics | 2.86 Mn | 2.11 Mn | -93,887.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9,182.00 |
| Dec 31, 2025 | 9,182.00 |
| Sep 30, 2025 | 205,492.00 |
| Sep 30, 2025 | 205,492.00 |
| Jun 30, 2025 | 278,307.00 |
| Jun 30, 2025 | 278,307.00 |
| Mar 31, 2025 | 275,642.00 |
| Mar 31, 2025 | 275,642.00 |
| Dec 31, 2024 | 292,071.00 |
| Dec 31, 2024 | 292,071.00 |
| Sep 30, 2024 | 232,434.00 |
| Sep 30, 2024 | 232,434.00 |
| Jun 30, 2024 | 239,821.00 |
| Jun 30, 2024 | 239,821.00 |
| Mar 31, 2024 | 244,685.00 |
| Mar 31, 2024 | 244,685.00 |
| Dec 31, 2023 | 261,272.00 |
| Dec 31, 2023 | 261,272.00 |
| Sep 30, 2023 | 219,848.00 |
| Sep 30, 2023 | 219,848.00 |